The genetics of type I interferon in systemic lupus erythematosus
Highlights
► Type I IFN appears to be a central pathway dysregulated in SLE. ► Most SLE patients have a prominent IFN gene signature in blood. ► Over half of the common alleles associated with SLE map into the type I IFN pathway. ► Rare, monogenic SLE-like diseases also show activation of type I IFN.
Introduction
SLE is characterized by IgG autoantibodies to highly conserved nuclear antigens such as double-stranded DNA (dsDNA), histones and ribonuclear proteins. Immune complexes comprised of IgG and self-antigens deposit in tissues and blood vessels, including skin, kidneys, and pleura/pericardium, leading to end-organ disease. Additional autoantibodies directly target cell surface antigens, causing cytopenias and other pathologies. Similar to most autoimmune diseases, human leukocyte antigen (HLA) genes are associated with increased SLE risk, with strongest evidence for the class II HLA alleles DRB1*15:01 and DRB1*03:01 [1]. Although the survival rate for SLE has improved greatly over the years, patients are 2.5 times more likely to die than the general population [2], and there is a pressing need to develop new therapies.
Here, we review evidence from genomic, candidate gene, and genomewide association studies (GWAS), together with recent findings from monogenic SLE and SLE-related diseases, that support the hypothesis that type I interferons (IFNs) are key factors in SLE pathogenesis.
Section snippets
Pleiotropic effects of type I IFN and related pathways
Type I IFNs (13 IFN-α isotypes, IFN-β, IFN-ɛ, IFN-κ, and IFN-ω) are produced primarily by plasmacytoid dendritic cells (pDCs), and are regulated by engagement of cell membrane or endosomal receptors, such as certain toll-like receptors (TLRs) (TLR 3, 7/8, 9), that recognize nucleic acids in viruses, bacteria and protozoa. Intracellular viral RNA and DNA are recognized by a specialized set of receptors (e.g. RIG-I, IFIH1) that also trigger type I IFN production. Type I IFN binds to the
The IFN gene expression signature and IFN-α in SLE
Using microarray gene expression analysis, we generated initial data in 1999 showing that about two-thirds of adult SLE patients exhibited elevated expression of type I IFN-inducible genes in peripheral blood cells, and coined the term ‘IFN signature’ [9••]. Additional groups reported similar findings in SLE [10••, 11, 12], and subsequently the IFN signature was found to be prominent in Sjögren's syndrome, dermatomyositis, subacute cutaneous lupus and discoid lupus erythematosus [13, 14, 15, 16
Genetic risk for SLE and the type I IFN pathway
An important development over the past 5 years has been the identification of genes that associate with SLE and that map into the type I IFN pathway. An initial candidate gene study by Sigurdsson et al. [36] found an association of the transcription factor interferon regulatory factor 5 (IRF5) with SLE. Further genetic and functional studies identified a single risk haplotype for IRF5 characterized by three functional alleles [37, 38•]. The non-risk haplotypes for IRF5 contain a splice site
Single gene lupus-related disorders of the type I IFN pathway
In addition to studying sporadic SLE, it is worthwhile to examine highly penetrant phenotypes with a clinical presentation that is similar to or shared with SLE. These single-gene, or Mendelian, disorders can offer insight into therapeutic targets for SLE. However, they may not be representative of sporadic SLE.
Recent data on rare single gene variants that lead to either SLE or SLE-like disease further support the idea that inappropriate activation of type I IFN is on the causal pathway for SLE
Type I IFN as a therapeutic target in SLE
Developing novel therapeutics for SLE is particularly important because there are so few effective therapies for SLE available today. The FDA recently approved Belimumab, a human monoclonal antibody that inhibits the B-lymphocyte stimulator (BLyS), for use in non-renal SLE, and it is the first SLE therapeutic approved in over five decades. The relatively modest clinical benefits reported in the pivotal trials for Belimumab suggest the optimal patient subset for this drug has not yet been
Conclusions
In aggregate, the evidence supporting the direct involvement of type I IFNs in SLE pathogenesis is quite compelling: (a) IFN-α immunotherapy can induce lupus [98]; (b) circulating immune complexes from SLE blood can initiate type I IFN production; (c) there are prominent IFN regulated gene and cytokine signatures in SLE; (d) polymorphisms in IFN pathway genes are associated with SLE in GWAS studies; and (e) several single gene disorders cause increased type I IFN and SLE or SLE-like symptoms.
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted:
• of special interest
•• of outstanding interest
Acknowledgements
We would like to thank A. Manoharan and H. Sun for their invaluable assistance in curating the published SLE literature for genetic associations.
References (98)
- et al.
The JAK-STAT pathway at twenty
Immunity
(2012) - et al.
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6
Immunity
(2003) - et al.
Induction of Fas ligand-mediated apoptosis by interferon-alpha
Clin Immunol
(2000) - et al.
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
J Exp Med
(2005) - et al.
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci
Nat Genet
(2008) Type I interferonopathies: a novel set of inborn errors of immunity
Ann NY Acad Sci
(2011)- et al.
Hereditary complement factor I deficiency
QJM
(1994) - et al.
Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi–Goutieres syndrome at the AGS1 locus
Nat Genet
(2006) - et al.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha
Clin Immunol
(2012)
Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE
Eur J Hum Genet
Mortality in systemic lupus erythematosus
Arthritis Rheum
Mechanisms of type-I-and type-II-interferon-mediated signalling
Nat Rev Immunol
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus
Science
Direct effects of type I interferons on cells of the immune system
Clin Cancer Res
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
Proc Natl Acad Sci USA
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
J Exp Med
Microarray analysis of interferon-regulated genes in SLE
Autoimmunity
Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray
Genes Immun
Peripheral blood gene expression profiling in Sjögren's syndrome
Genes Immun
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis
Ann Neurol
An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity
Mol Med
The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score
Br J Dermatol
Gene expression profiling in human autoimmunity
Immunol Rev
Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes
Diabetes
Serum interferon levels in patients with systemic lupus erythematosus
Arthritis Rheum
Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha production acting on leucocytes resembling immature dendritic cells
Clin Exp Immunol
A pivotal role for the natural interferon-alpha producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus
J Exp Med
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
Immunity
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Nature
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes
J Exp Med
Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus
Ann Rheum Dis
Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus
Lupus
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Arthritis Rheum
Interferon-alpha regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study
Arthritis Rheum
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus
PLoS Med
Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus
Arthritis Rheum
Antibodies to alpha-interferon in a patient with systemic lupus erythematosus
J Immunol
Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus
Arthritis Rheum
Presence of interferon and anti-interferon in patients with systemic lupus erythematosus
Rheumatol Int
Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia
J Interferon Cytokine Res
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
Am J Hum Genet
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus
Nat Genet
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus
Proc Natl Acad Sci USA
IFN regulatory factor 5 is required for disease development in the Fc-gamma-RIIB−/− Yaa and Fc-gamma-RIIB−/− mouse models of systemic lupus erythematosus
J Immunol
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus
Ann Rheum Dis
Genome-wide profiling of target genes for the systemic lupus erythematosus-associated transcription factors IRF5 and STAT4
Ann Rheum Dis
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX
N Engl J Med
Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus
Nat Genet
Cited by (99)
Interferon Signature Analysis
2022, Encyclopedia of Infection and ImmunitySystemic Lupus Erythematosus
2022, Comprehensive PharmacologyWhat can we learn from DNA methylation studies in lupus?
2022, Clinical ImmunologyCitation Excerpt :This complement component is responsible of inhibiting IFNα production by innate immune cells [49]. Not only monogenic forms, but also susceptibility alleles have also been described in Type I interferon pathway (reviewed in [47]), linking once again this pathway with the development of the disease. In the case of DNA methylation, the hypomethylated profile on interferon-signaling pathway is also relevant in neutrophils and low-density granulocytes [50], CD19+ B cells and CD14+ monocytes [51], CD8+ T cells [52] and memory, regulatory and naïve CD4+ T cells [51,53,54].
Genes and genetics in human SLE
2020, Systemic Lupus Erythematosus: Basic, Applied and Clinical AspectsDistinct RBC alloantibody responses in type 1 interferon-dependent and -independent lupus mouse models
2023, Frontiers in ImmunologyLupus, DNA Methylation, and Air Pollution: A Malicious Triad
2022, International Journal of Environmental Research and Public Health